

was also obtained. Finally the retina was fixed, stained and mounted, and a second map of the blood vessels made. By comparing the two maps the electrode sites could be related to the retinal structure.

According to the map, one electrode site was at the circle marked in Fig. 3. The optic nerve fibres are seen dragged aside as the tip moved over the artery. Apart from the two cells shown, there was none within a radius of 500 μ from the circle except for one at the zero of the scale. The large and smaller cells of Fig. 3 appear to be correlated with the large and smaller spikes of Fig. 2, which were recorded from this locality.

Conclusions. The retinal spikes arise from large ganglion cells rather sparsely scattered in the ganglion layer of the retina (Fig. 3). The cell has a wide-thrown ramification of branching filaments extending some 0.5 mm. in all directions. These cells appear to collect impulses from a wide region of the retina, and to be ill-adapted to discriminate form and colour.

W. A. H. RUSHTON

Trinity College, Cambridge.

Sept. 13.

¹ Granit, R., "Sensory Mechanisms of the Retina" (Oxford Univ. Press, 1947).

² Palmgren, A., *Acta Zool.*, **29**, 378 (1948).

Role of Co-factors in the Inhibition of Bacterial Viruses by the Somatic Antigens of *Shigella sonnei*

DURING the course of an investigation¹ on the susceptibility of *Sh. sonnei* Phase I and II² and their phage-resistant variants to the *T* series of bacterial viruses, it was found that the Phase I micro-organism was lysed only by *T*₂ and *T*₆, whereas the Phase II bacillus was susceptible to *T*₃, *T*₄ and *T*₇, as well as *T*₂ and *T*₆. Solutions of the chemically purified and immunologically specific somatic antigens derived from Phase I and II bacilli³ were incubated at 37° C. with approximately 2,000 particles per ml. of the appropriate viruses in an ammonium lactate medium (*F*)⁴. The bacteriophages employed were kindly supplied by Dr. Mark Adams, of New York University. Fresh stocks of the *T*₃ and *T*₇ viruses were prepared in nutrient broth using *E. coli* B as the host cell. *T*₂ and *T*₆ were prepared in *F* medium, and the *T*₄ virus in *F* medium containing 5 micrograms of 1-tryptophane per ml. When 0.1 ml. of the mixture was assayed on nutrient agar by the Hershey poured-plate technique⁵, there was no evidence that the lipocarbohydrate-protein antigens, even in concentrations as high as 0.1 mgm. per ml., would inhibit the lytic action of the viruses. This indicated that the purified antigens were incapable of preventing adsorption of the virus by the bacterial cell. These observations appear to be contrary to those of other investigators⁶, who found that extracts of a variety of micro-organisms, which presumably contained immunologically active carbohydrates, have the power of preventing the adsorption of bacterial viruses to the host cell.

Further investigation has now revealed that the somatic antigen of Phase II *Sh. sonnei* in the presence of broth does inhibit the lytic action of *T*₃, *T*₄ and *T*₇ on the homologous micro-organism. On the other hand, the same antigen fails to inhibit the action of *T*₂ and *T*₆. It appeared that some constituent of the broth plays an essential part in the selective inhibition of *T*₃, *T*₄ and *T*₇ by the Phase II antigen. Anderson⁷

has shown that 1-tryptophane serves as a co-factor in promoting the absorption of *T*₄ and *T*₇ on *E. coli*. It seemed possible that this amino-acid might likewise be involved in the combination of *T*₃, *T*₄ and *T*₇ with the cell-free somatic antigen derived from *Sh. sonnei* Phase II.

Inhibition of bacterial viruses *T*₃, *T*₄ and *T*₇ by the somatic antigen of Phase II *Sh. sonnei*

Bacterial virus tested	Medium used	Final concentration of Phase II antigen in virus-antigen mixture*		
		0.1 mgm.	0.01 mgm.	0.001 mgm.
<i>T</i> ₃	<i>F</i> Broth	0	0	0
	<i>F</i> plus 0.2 mgm. 1-tryptophane per ml.	99	65	12
	<i>F</i>	0	0	0
<i>T</i> ₄	<i>F</i> Broth	0	0	0
	<i>F</i> plus 0.2 mgm. 1-tryptophane per ml.	99	96	93
	<i>F</i>	98	85	63
<i>T</i> ₇	<i>F</i> Broth	0	0	0
	<i>F</i> plus 0.2 mgm. 1-tryptophane per ml.	98	93	81
	<i>F</i>	0	0	0

* The figures represent the percentage of virus inactivated. *F* = ammonium lactate medium.

When 0.2 mgm. of 1-tryptophane per ml. was added to *F*, as little as 1 microgram per ml. of the Phase II antigen inhibited *T*₄, but had no effect upon *T*₃ and *T*₇, as can be seen from the accompanying table. Since the latter viruses are inhibited by comparable quantities of the Phase II antigen in the presence of broth, it would appear that in these instances still other co-factors are involved.

The antigen of Phase I *Sh. sonnei* caused no inhibition of *T*₂ and *T*₆ when tested with Phase I micro-organisms, or of *T*₃, *T*₄ and *T*₇ when tested with Phase II bacilli, even in the presence of broth. It is evident, therefore, that the inhibitory action of the Phase II antigen is highly specific, and that a co-factor is required in order for it to block combination of *T*₃, *T*₄ and *T*₇ with the host cell.

These experiments leave certain facts still unexplained. It is not yet known whether the virus combines with the protein, the lipid or the carbohydrate constituent of the somatic antigen; but work now in progress should establish this point. The nature of the co-factors present in broth which permits *T*₃ and *T*₇ to be inhibited by the antigen is not yet known. It would appear, however, that in the case of Phase II *Sh. sonnei* the substance which combines with *T*₃, *T*₄ or *T*₇ is a constituent of the lipocarbohydrate-protein complex distributed at the bacterial surface, and that this combination occurs only when an essential co-factor is present.

ELIZABETH M. MILLER

WALTHER F. GOEBEL

Rockefeller Institute for Medical Research,
New York 21, N.Y.

May 25.

¹ Miller, E. M., results submitted in a thesis to the Graduate School of Arts and Science, New York University, in partial fulfilment of the requirements for the degree of master of science.

² Wheeler, K., and Mickle, F. L., *J. Immunol.*, **51**, 257 (1945).

³ Baker, E. E., Goebel, W. F., and Periman, E., *J. Exp. Med.* (in the press).

⁴ Schliesinger, M., *Z. Hyg. Infektionskrankh.*, **114**, 746 (1932).

⁵ Hershey, A. D., Kalmanson, G. M., and Bronfenbrenner, J., *J. Immunol.*, **48**, 267 (1943).

⁶ Burnet, F. M., *Biol. Rev. Cambridge Phil. Soc.*, **9**, 332 (1934). Gough, G. A. C., and Burnet, F. M., *J. Path. and Bact.*, **38**, 301 (1934). Levine, P., and Frisch, A. W., *J. Exp. Med.*, **59**, 213 (1934). Craigie, J., *Bact. Rev.*, **10**, 73 (1946).

⁷ Anderson, T. F., *J. Cell. Comp. Physiol.*, **25**, 17 (1945); *J. Bact.*, **55**, 637, 651, 659 (1948).